This peptide classification describes structure and identity. It separates defined amino-acid sequences from fragments, modified analogues, metal complexes, mixtures and non-peptide small molecules. This list of peptides is written solely for laboratory research use. It provides no guidance for human or veterinary use and makes no claim about experimental outcomes.<\/p>\n
These types of peptides and adjacent compounds are organised here by what each material is, not by what it is claimed to do. A grouping based on a claimed effect is not a chemical classification. Structural peptide classes instead provide a disciplined starting point for naming, analytical planning and documentation. The wider knowledge hub<\/a> connects this framework with evidence review, while the research-peptide category<\/a> remains a catalogue route rather than proof of equivalence.<\/p>\n A peptide contains amino-acid residues joined through amide bonds: the usual peptide bond links C-1 of one residue to N-2 of the next, while links through other amide bonds are called isopeptide bonds. Chain length is one useful ordering principle in a list of peptides: two residues form a dipeptide, three a tripeptide, chains of fewer than about 10\u201320 residues may also be called oligopeptides, and longer chains polypeptides, with approximate and context-dependent limits. The peptide vs protein transition is a matter of scientific convention and context, not a sharp natural boundary fixed by one universally decisive residue count.<\/p>\n Architecture adds another identity layer. A linear peptide has an open chain, whereas a cyclic peptide contains a covalent ring. PT-141<\/a>, for example, is a cyclic heptapeptide with side-chain ring closure between Asp and Lys. Its condensed notation also identifies N-terminal acetylation and a D-phenylalanine residue.<\/p>\n Sequence records the order of residues from the N-terminus to the C-terminus, conventionally written left to right. It may use three-letter notation, such as Gly-His-Lys, or a one-letter code. Both must preserve that order and distinguish D- from L-amino acids where relevant. N-terminal acetylation, C-terminal amidation, non-natural residues and other modifications form part of molecular identity rather than optional descriptive detail. A shared chain length therefore does not make two peptide types the same substance.<\/p>\n A defined-sequence peptide is specified by the identity and order of its amino-acid residues, together with any terminal or side-chain modifications. Selank<\/a> is a linear heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP. BPC-157<\/a> is a pentadecapeptide comprising 15 residues, with the sequence GEPPPGKPADDAGLV. A familiar short name alone is not sufficient.<\/p>\n Further defined-sequence entries include the linear nonapeptide DSIP peptide<\/a>, the synthetic linear tetrapeptide Epithalon<\/a>, N-terminally acetylated 28-residue thymosin alpha-1<\/a>, the amidated 28-mer VIP peptide<\/a> and C-terminally amidated kisspeptin-10<\/a>. Oxytocin acetate<\/a> is the acetate salt of a cyclic, C-terminally amidated nonapeptide, whereas SS-31 peptide<\/a> is a synthetic, amidated tetrapeptide containing non-natural and D-configured residues.<\/p>\n A fragment represents a defined section of a longer reference sequence. Semax<\/a> is the linear heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP): its first four residues correspond to the ACTH(4\u20137) fragment, followed by Pro-Gly-Pro. In the analytical literature the designation TB-500<\/a> is used for the N-terminally acetylated heptapeptide Ac-LKKTETQ, corresponding to residues 17\u201323 of thymosin beta-4, while other work uses the same designation for the full-length 43-residue molecule. Without a traceable batch specification the designation alone does not fix a molecular structure; specification and analytics must state which form was examined. Literature about a full-length source protein is not evidence for a fragment; molecular form, model and endpoint must match.<\/p>\n HGH fragment 176-191<\/a> is the C-terminal 16-residue segment of mature human growth hormone, while AOD-9604 peptide<\/a> is a synthetic N-tyrosyl analogue of the hGH C-terminal fragment 177\u2013191. PEG MGF<\/a> is a PEGylated synthetic analogue of an E-domain peptide associated with IGF-1Ec, and its precise sequence and conjugation site remain batch-documentation questions.<\/p>\n An analogue contains deliberate structural changes relative to a reference sequence, such as substitutions, extensions, terminal changes, non-natural residues or attached groups. The word \u201canalogue\u201d identifies a relationship; it does not establish substance equivalence. Retatrutide<\/a> is a synthetic, lipidated peptide with a 39-residue main chain containing non-natural residues and is described in the catalogue as a multi-receptor agonist. That pharmacological description does not replace its structural identity, nor does similarity to another sequence make their documentation interchangeable.<\/p>\n IGF-1 LR3<\/a> is a synthetic recombinant IGF-I analogue defined by an N-terminal extension and a Glu3-to-Arg substitution, and tesamorelin peptide<\/a> is an N-terminally trans-3-hexenoylated GHRH(1-44) analogue. Ipamorelin<\/a> is a synthetic, C-terminally amidated pentapeptide containing non-proteinogenic and D-configured residues.<\/p>\n A metal complex contains a ligand coordinated to a metal ion. The designation GHK-Cu<\/a> indicates coordination of copper(II) by the tripeptide Gly-His-Lys, but does not fix a single coordination species: the predominant form depends, among other factors, on pH and stoichiometry. Free GHK and the copper(II)-coordinated forms are different chemical species. Records and analytical results must state which form was examined.<\/p>\n MOTS-c<\/a> is a 16-amino-acid sequence encoded by a small open reading frame in the mitochondrial 12S rRNA region and is placed within the research field of mitochondrial-derived peptides. \u201cMitochondrial-derived\u201d describes the sequence’s reported origin and a field of investigation. It is not a quality designation, purity statement or prediction about a study result.<\/p>\n A blend contains multiple named components in a defined product configuration. GLOW<\/a>, KLOW<\/a> and Wolverine<\/a> belong to this compositional category. For the Wolverine composition, BPC-157 and TB-500 are the named components. Each component requires its own unambiguous identity, documented amount and suitable analytical support, and the overall mixture requires attributable batch records. Literature about a component does not establish the mixture’s identity or quality.<\/p>\n Catalogue proximity does not turn every research compound into a peptide. SLU-PP-332<\/a> has no peptide-chain architecture. Separately, Billon et al. report the identification of SLU-PP-332 as a synthetic pan-ERR agonist targeting all three ERR subtypes, with the highest potency for ERRα; the reported experiments used a skeletal-muscle cell line and mice and provide no human data (PMID 36988910<\/a>). The ERR agonist overview<\/a> explains that receptor-family classification separately. Keeping non-peptides distinct stops a catalogue label from overriding chemical identity.<\/p>\n Despite the catalogue term 5-Amino-1MQ peptide<\/a>, 5-amino-1-methylquinolinium is a quinolinium cation without an amino-acid chain or peptide bonds.<\/p>\n Solvents and laboratory water may support controlled laboratory workflows, but they are ancillary materials rather than compound classes within the peptide assortment. Their identity, lot trail and specifications remain independent of the research substance. The preserved laboratory water guide<\/a> explains this material category and its documentation boundary.<\/p>\n The catalogue term HCG peptide<\/a> likewise does not make human chorionic gonadotropin a short, single-chain peptide: hCG is a heterodimeric, glycosylated glycoprotein hormone.<\/p>\n Compound class is a filing and interpretation tool. It does not establish purity, batch quality, origin, suitability for a specific experiment or comparability between two supplied materials. A purity result can be stated only for the tested sample, within the scope of the attributable COA and analytical method; extending it to the batch requires documented, representative sampling.<\/p>\n Groupings such as \u201cskin peptides\u201d, \u201cgrowth peptides\u201d or other claimed-effect lists are not chemical ordering systems. They combine structurally different materials around an asserted theme and can obscure whether a cited paper examined a peptide, fragment, complex, mixture or small molecule. A responsible comparison within a list of peptides begins with exact molecular identity, then identifies the experimental model and endpoint. The study-models guide<\/a> explains why observations must remain qualified by in vitro, preclinical, human-study or other evidence context.<\/p>\n Class helps determine which analytical questions should be asked. For a defined peptide, sequence, expected mass and modifications guide identity assessment. A cyclic structure requires the ring closure to be represented. A metal complex requires evidence that distinguishes complex from free ligand. A mixture requires component-level identification and quantity information. A non-peptide small molecule may call for structure-appropriate chromatographic and spectrometric methods rather than assumptions borrowed from peptide analysis.<\/p>\n No method follows automatically from the class label alone. The laboratory must select and validate methods for the material, matrix and question. HPLC can separate detected sample components and report a method-dependent relative area result; mass spectrometry can support an expected-mass assignment. Neither result should be stretched beyond its scope. The purity, HPLC and MS guide<\/a> covers these analytical boundaries.<\/p>\n Only batch documentation can connect a reported result to supplied material. The designation, batch code, test date, method and result must remain attributable to the same record. A sequence in a database does not authenticate a batch. The guide to understanding the COA<\/a> sets out how those fields work together. Published research and batch analytics remain separate evidence streams: one describes an experiment, while the other documents the material tested under stated methods.<\/p>\n No. Identity also depends on residue order, D- or L-configuration, terminal modifications and, where applicable, ring closure. An equal residue count does not make two substances identical.<\/p>\n No. A fragment is a distinct molecular section with its own identity. Literature or documentation for the full sequence does not authenticate the fragment batch.<\/p>\n No. GHK is the free ligand, whereas GHK-Cu designates copper(II)-coordinated forms without fixing a single coordination species. A result for one form does not document the others.<\/p>\n No. Each component requires separate identification, and the mixture requires its own attributable batch records. A component certificate therefore describes that component alone, not the composition as supplied.<\/p>\n An HPLC result is a method-dependent relative area result for the tested sample, within the limits of the declared method. Alone, it establishes neither the complete structure nor every possible impurity, and extending the result to the batch requires documented, representative sampling.<\/p>\n All materials in this list of peptides and adjacent compounds are for laboratory research use only. They are not for human or veterinary use. Compound classification supports precise naming, method selection and traceable documentation; it does not establish a biological outcome, universal purity or equivalence between materials.<\/p>\n This peptide classification describes structure and identity. It separates defined amino-acid sequences from fragments, modified analogues, metal complexes, mixtures and non-peptide small molecules. This list of peptides is written solely for laboratory research use. It provides no guidance for human or veterinary use and makes no claim about experimental outcomes. These types of peptides and […]<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":445,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-457","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages\/457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/comments?post=457"}],"version-history":[{"count":1,"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages\/457\/revisions"}],"predecessor-version":[{"id":1465,"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages\/457\/revisions\/1465"}],"up":[{"embeddable":true,"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages\/445"}],"wp:attachment":[{"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/media?parent=457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What defines a peptide<\/h2>\n
Peptide types by architecture \u2014 linear, cyclic and modified forms<\/h2>\n
Amino-acid sequence and naming<\/h2>\n
Classes in the research catalogue<\/h2>\n
Defined-sequence peptides<\/h3>\n
Fragments and sequence-derived peptides<\/h3>\n
Analogues and modified sequences<\/h3>\n
Metal complexes<\/h3>\n
Mitochondrial-derived peptides<\/h3>\n
Blends and defined mixtures<\/h3>\n
Non-peptide research compounds<\/h3>\n
Ancillary laboratory materials<\/h3>\n
Why class is not a claim<\/h2>\n
Class, batch and documentation<\/h2>\n
Frequently asked questions<\/h2>\n
Does chain length alone identify a peptide?<\/h3>\n
Is a fragment the same as the full reference sequence?<\/h3>\n
Are GHK and GHK-Cu the same chemical form?<\/h3>\n
Does documentation for one component authenticate a blend?<\/h3>\n
What does an HPLC result say about purity?<\/h3>\n
Research-use statement<\/h2>\n
Sources<\/h2>\n
\n